Creatine kinase BB activity in serum of patients with acute stroke: correlation with the severity of brain damage

Capocchi, Giuseppe; Tassi, C; Ricci, Stefano; Zampolini, Mauro; Fausti, R; Rossi, Aroldo

doi:10.1007/bf02333663

Cited by 15 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CK in the isoforms of CK-MM and CK-MB have been widely studied for the diagnosis of myocardial infarction 22 , but less is known about CK-BB disease relevance. In concordance with our results, CK-BB has been well reported to immediately increase in blood circulation and CSF following acute cerebral injuries, including cerebrovascular traumatisms, meningitis and strokes 23 – 25 , and its role as a plausible diagnostic biomarker for ischemic stroke has been previously postulated 26 , 27 . CK-BB provenance has been slightly controversial; some studies have proven that astrocytes and neurons are the main CK-BB source, whereas others, including us, could only proof that astrocytes express CK-BB in brain 28 .…”

Section: Discussionsupporting

confidence: 92%

Characterization of the rat cerebrospinal fluid proteome following acute cerebral ischemia using an aptamer-based proteomic technology

Simats

García‐Berrocoso

Ramiro

et al. 2018

Sci Rep

View full text Add to dashboard Cite

The limited accessibility to the brain has turned the cerebrospinal fluid (CSF) into a valuable source that may contribute to the complete understanding of the stroke pathophysiology. Here we have described the CSF proteome in the hyper-acute phase of cerebral ischemia by performing an aptamer-based proteomic assay (SOMAscan) in CSF samples collected before and 30 min after male Wistar rats had undergone a 90 min Middle Cerebral Artery Occlusion (MCAO) or sham-surgery. Proteomic results indicated that cerebral ischemia acutely increased the CSF levels of 716 proteins, mostly overrepresented in leukocyte chemotaxis and neuronal death processes. Seven promising candidates were further evaluated in rat plasma and brain (CKB, CaMK2A, CaMK2B, CaMK2D, PDXP, AREG, CMPK). The 3 CaMK2 family-members and CMPK early decreased in the infarcted brain area and, together with AREG, co-localized with neurons. Conversely, CKB levels remained consistent after the insult and specifically matched with astrocytes. Further exploration of these candidates in human plasma revealed the potential of CKB and CMPK to diagnose stroke, while CaMK2B and CMPK resulted feasible biomarkers of functional stroke outcome. Our findings provided insights into the CSF proteome following cerebral ischemia and identified new outstanding proteins that might be further considered as potential biomarkers of stroke.

show abstract

Section: Discussionsupporting

confidence: 92%

Characterization of the rat cerebrospinal fluid proteome following acute cerebral ischemia using an aptamer-based proteomic technology

Simats

García‐Berrocoso

Ramiro

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Increases in nucleoside-diphosphate kinase 1 have been reported in blood (5 ), and increases in creatine kinase B have been reported in both blood (29 ) and CSF (30,31 ).…”

Section: Discussionmentioning

confidence: 97%

Proteomic Analysis of Cerebrospinal Fluid Changes Related to Postmortem Interval

et al. 2006

View full text Add to dashboard Cite

Background:The study of proteins with altered production in postmortem cerebrospinal fluid (CSF) compared with antemortem CSF may improve the understanding of biochemical changes that occur immediately after death. Methods: Two CSF samples (1 antemortem and 1 postmortem) were collected from 7 patients and analyzed by 2-dimensional gel electrophoresis. An analysis was also performed to identify proteins that showed a correlation between concentration change and postmortem interval. Tandem mass spectrometry was used to identify the proteins. Results: Fifty-four protein spots were identified that showed a consistent and significant change in concentration in the postmortem CSF of all 7 patients (>3.5-fold, P <0.01). The proteins in these spots derive from a variety of functional groups, including cytoskeletal proteins, enzymes involved in glycolysis, and proteins that prevent oxidative stress. Fourteen protein spots were found to have an increase in production that correlated with postmortem interval. Conclusions: Changes in protein production of postmortem vs antemortem CSF were studied. The proteins observed to change production in the postmortem CSF include several proteins previously observed as potential stroke biomarkers.

show abstract

“…Despite their limited validity, some biochemical markers are currently used as indicators of brain damages [16,17] including neuron-specific enolase (NSE) [18], astroglial protein S-100b [19], myelin basic protein (MBP) [20], creatin phosphokinase isoenzyme BB (CK-BB) [21], tau [22], thrombomodulin (Tm), glial fibrillary acidic protein (GFAP), adenylkinase, lactate, lactate deshydrogenase, aspartate aminotransferase, glutathione, vasointestinal neuropeptide, and 7B2-specific neuropetide [17]. Recently, Reynolds et al [23] developed a panel of five proteins (S-100b, B-type neurotrophic growth factor, von Willebrand factor, matrix metalloproteinase-9, and monocyte chemotactic protein-1), which appeared capable to diagnose a stroke with sensitivity and specificity above 90%.…”

Section: Introductionmentioning

confidence: 99%

ApoC‐I and ApoC‐III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke

et al. 2004

View full text Add to dashboard Cite

Early diagnosis and immediate therapeutic interventions are crucial factors to reduce the damage extent and the risk of death. Currently, the diagnosis of stroke relies on neurological assessment of the patient and neuro-imaging techniques including computed tomography and/or magnetic resonance imaging scan. An early diagnostic marker of stroke, ideally capable to discriminate ischemic from hemorrhagic stroke would considerably improve patient acute management. Using surface-enhanced laser desorption/ionization (SELDI) technology, we aimed at finding new early diagnostic plasmatic markers of stroke. Strong anionic exchange (SAX) SELDI profiles of plasma samples from 21 stroke patients were compared to 21 samples from healthy controls. Seven peaks appeared to be differentially expressed with significant p values (p < 0.05). Proteins were stripped from the SAX chips, separated on a one-dimensional electrophoresis (1-DE) gel and stained using mass spectrometry (MS)-compatible silver staining. Following in-gel tryptic digestion, the peptides were analyzed by MS. Four candidate proteins were identified as apolipoprotein CI (ApoC-I), apolipoprotein CIII (ApoC-III), serum amyloid A (SAA), and antithrombin-III fragment (AT-III fragment). Assessment of ApoC-I and ApoC-III levels in plasma samples using a sandwich enzyme-linked immunosorbent assay (ELISA) allowed to distinguish between hemorrhagic (n = 15) and ischemic (n = 16) stroke (p < 0.001). To the best of our knowledge, ApoC-I and ApoC-III are the first reported plasmatic biomarkers capable to accurately distinguish between ischemic and hemorrhagic stroke in a small number of patients. It requires further investigation in a large cohort of patients.

show abstract

Creatine kinase BB activity in serum of patients with acute stroke: correlation with the severity of brain damage

Cited by 15 publications

References 13 publications

Characterization of the rat cerebrospinal fluid proteome following acute cerebral ischemia using an aptamer-based proteomic technology

Characterization of the rat cerebrospinal fluid proteome following acute cerebral ischemia using an aptamer-based proteomic technology

Proteomic Analysis of Cerebrospinal Fluid Changes Related to Postmortem Interval

ApoC‐I and ApoC‐III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke

Contact Info

Product

Resources

About